Genome editing, represented by CRISPR/Cas9, facilitates somatic and germline gene modifications in many species, including humans. However, one of key issues, off-target mutation deserves special consideration prior to clinical applications. We herein discuss the importance of risk information on genome editing for obtaining legitimate patient consent and social acceptance.
Keywords: CRISPR/Cas9; clinical application; genome editing; informed consent; off-target mutation; society.
Copyright © 2015 Elsevier Ltd. All rights reserved.